This story was adapted from Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
If Kamala Harris wins the presidential election, it’s pretty much status quo in the little corner of the world where biotech meets Wall Street.
That might not be seen as good news for everyone, given differing views about the Democrats’ zeal for the Inflation Reduction Act. But whomever Harris and her team would appoint to run the FDA isn’t likely to be a radical policy departure from current commissioner Robert Califf, assuming he steps down.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
